BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsFinancing

$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor

The Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62% discount to its closing price on March 22,...

Open original release

Related news

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-05-27 08:00 EST

Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity

IBRXImmunityBio2026-03-31 11:30 EST

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

LYELLyell Immunopharma2026-03-09 12:00 EST

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

ANABAnaptysBio, Inc.2026-03-27 13:00 EST

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

MDNAMedicenna Therapeutics Corp.2026-05-28 13:10 EST

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

TPSTTempest Therapeutics2026-03-23 12:00 EST

Tempest Therapeutics Announces Up To $6 Million Private Placement

GLSIGreenwich LifeSciences2026-04-14 10:00 EST

Greenwich LifeSciences Provides Update on Financing Strategy

MDNAMedicenna Therapeutics Corp.2026-05-19 11:00 EST

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

ANABAnaptysBio, Inc.2026-03-27 13:00 EST

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-07-28 13:00 EST

Enlivex Announces $400,000,000 Private Placement

ENLVEnlivex Therapeutics2026-07-20 13:00 EST

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

ENLVEnlivex Therapeutics2026-06-02 08:00 EST

ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026

ENLVEnlivex Therapeutics2026-06-01 08:00 EST

Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

ENLVEnlivex Therapeutics2026-05-28 08:00 EST

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board

Stock data

Close
4.26 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States